Pfizer Inc and Astellas announced final overall survival (OS) results from the Phase III EMBARK study evaluating Xtandi (enzalutamide), in combination with leuprolide and as monotherapy, in men with… read more.
Novartis presented new Pluvicto(lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition trial in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2025…. read more.
Researchers report that overall survival is significantly longer among prostate cancer patients at high-risk of biochemical recurrence who are treated with combination enzalutamide and leuprolide rather than with… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that a presentation related to Peyronie’s disease, or PD, and Xiaflex (collagenase clostridium histolyticum, or CCH, injection 0.9 mg) will… read more.
Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced that nine presentations related to Peyronie’s disease, or PD, and XIAFLEX® (collagenase clostridium histolyticum, injection 0.9 mg) will be shared… read more.
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical… read more.
A randomized controlled trial aimed to determine whether providing information on patient risk for advanced colorectal neoplasia (ACN) to patients and providers affects colorectal cancer (CRC) screening uptake…. read more.
In a preclinical study, researchers found tamoxifen encourages uterine cell growth; the findings could change how some breast cancers are treated in the future Studies show that people… read more.
Iterum Therapeutics plc announced the U.S. launch of Orlynvah (sulopenem etzadroxil and probenecid) oral tablets. The FDA had approved Orlynvah for adult women with uncomplicated urinary tract infections… read more.
Basilea Pharmaceutica announced that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil (Exblifep), a clinical phase… read more.
In a new study aimed at identifying the best approach to promote colorectal cancer screening in adults ages 45 to 49, UCLA researchers found that simply mailing a… read more.
About one quarter of patients with muscle-invasive bladder cancer (MIBC) may be treated and derive a benefit with the current standard chemotherapy. To better understand why some tumors… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
